Disclosure Of First-Time Adoption [Text Block]

ABIONYX Pharma - Filing #2810725

Concept	As at 2023-12-31	2023-01-01 to 2023-12-31	2023-01-01 to 2023-12-31	As at 2023-12-31	2023-01-01 to 2023-12-31	As at 2023-12-31	2023-01-01 to 2023-12-31	2023-01-01 to 2023-12-31	2023-01-01 to 2023-12-31	As at 2023-12-31	2023-01-01 to 2023-12-31	As at 2023-12-31	As at 2023-12-31	As at 2023-12-31	2022-01-01 to 2022-12-31	2022-01-01 to 2022-12-31	2022-01-01 to 2022-12-31	As at 2022-12-31	As at 2022-12-31	2022-01-01 to 2022-12-31	As at 2022-12-31	As at 2022-12-31	As at 2022-12-31	As at 2022-12-31	As at 2022-12-31	2022-01-01 to 2022-12-31	2022-01-01 to 2022-12-31	2022-01-01 to 2022-12-31	As at 2021-12-31	As at 2021-12-31	As at 2021-12-31	As at 2021-12-31	As at 2021-12-31	As at 2021-12-31	As at 2021-12-31
Disclosure of first-time adoption [text block]	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Disclosure of comparative information prepared under previous GAAP [text block]	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Disclosure of comparative information prepared under previous GAAP [abstract]
Disclosure of comparative information prepared under previous GAAP [line items]
Equity	158,000 EUR	—	—	7 922 EUR	—	6 341 EUR	—	—	—	12 572 EUR	—	1 623 EUR	103,000 EUR	193,000 EUR	—	—	—	7 169 EUR	192,000 EUR	—	8 599 EUR	2 937 EUR	229,000 EUR	1 418 EUR	126,000 EUR	—	—	—	201,000 EUR	169 829 EUR	10 677 EUR	10,000 EUR	179 214 EUR	87,000 EUR	1 396 EUR
Comprehensive income	—	3 575 EUR	—	—	—	—	—	—	—	—	—	—	—	—	—	—	3 985 EUR	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Profit (loss)	—	3 518 EUR	0 EUR	—	0 EUR	—	3 518 EUR	0 EUR	0 EUR	—	0 EUR	—	—	—	0 EUR	0 EUR	4 206 EUR	—	—	4 206 EUR	—	—	—	—	—	0 EUR	0 EUR	0 EUR	—	—	—	—	—	—	—